这有一段话，请牛人翻译，翻译好的追分（2）
'AOBOcontinuestobeanaggressivebrandconsolidatorinChina'sconsumerhealthcaremarket.Weha...
'AOBO continues to be an aggressive brand consolidator in China's consumer healthcare market. We have successfully executed the integration of several acquisitions and plan to continue to seek out strong targets like CCXA that can leverage our solid marketing, sales, and distribution platforms,' concluded Liu.
The monetary exchange rate used for this transaction is US$1.00 : RMB 7.55
About American Oriental Bioengineering, Inc.
American Oriental Bioengineering is a leading, fully integrated, plant based pharmaceutical and plant based nutraceutical company dedicated to improving health through the development, manufacture and commercialization of modernized plant based products in China.
Safe Harbor Statement
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the Company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
SOURCE American Oriental Bioengineering, Inc.
Source: PR Newswire (September 6, 2007 - 8:30 AM EDT) 展开
The monetary exchange rate used for this transaction is US$1.00 : RMB 7.55
About American Oriental Bioengineering, Inc.
American Oriental Bioengineering is a leading, fully integrated, plant based pharmaceutical and plant based nutraceutical company dedicated to improving health through the development, manufacture and commercialization of modernized plant based products in China.
Safe Harbor Statement
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the Company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
SOURCE American Oriental Bioengineering, Inc.
Source: PR Newswire (September 6, 2007 - 8:30 AM EDT) 展开
1个回答
展开全部
“在中国的消费保健品市场美国东方生物技术有限公司是一个积极的品牌代理商。目前我们已经成功地执行了整合的几起收购，并计划继续寻求像CCXA一样的目标，以利用我们营销来打造一个坚实的销售和分销的平台。”刘先生在结束发言时指出。
用于这项交易的货币汇率是1.00美元：人民币7.55
美国东方生物技术有限公司
美国东方生物技术，是一个领先的，完全集成的，以植物为主的制药和植物为主Nutraceutical公司该公司致力于改善健康，通过在中国开发、制造和商业领域的现代化，以植物为主的产品。
安全海关声明
本新闻稿中包含有前瞻性声明所确定的改革法案于1995年发表。前瞻性陈述包括有关计划，目标，目标，战略，未来事件或业绩，并基本假设和其他陈述是除历史事实声明之外的。但这些发言都受到不确定因素和风险，包括但不限于：产品和服务的需求和接受，技术的变革，经济状况，影响竞争和定价，政府规例，和其他风险包含在报告中提出，由该公司与证券及交易委员会的文件。所有这些声明中，无论是书面还是口头，以及是否取得或由他人代签，都作为明确的资格，警告声明与任何其他警示声明，其中可能伴随有此声明。此外，该公司还需承担一切义务一切更新此声明以反映事件或情况后，并明确表示日期。
源于 美国东方生物技术有限公司
资料来源：美通社（ 2007年9月6日-上午8时3 0分美国东部时间）
用于这项交易的货币汇率是1.00美元：人民币7.55
美国东方生物技术有限公司
美国东方生物技术，是一个领先的，完全集成的，以植物为主的制药和植物为主Nutraceutical公司该公司致力于改善健康，通过在中国开发、制造和商业领域的现代化，以植物为主的产品。
安全海关声明
本新闻稿中包含有前瞻性声明所确定的改革法案于1995年发表。前瞻性陈述包括有关计划，目标，目标，战略，未来事件或业绩，并基本假设和其他陈述是除历史事实声明之外的。但这些发言都受到不确定因素和风险，包括但不限于：产品和服务的需求和接受，技术的变革，经济状况，影响竞争和定价，政府规例，和其他风险包含在报告中提出，由该公司与证券及交易委员会的文件。所有这些声明中，无论是书面还是口头，以及是否取得或由他人代签，都作为明确的资格，警告声明与任何其他警示声明，其中可能伴随有此声明。此外，该公司还需承担一切义务一切更新此声明以反映事件或情况后，并明确表示日期。
源于 美国东方生物技术有限公司
资料来源：美通社（ 2007年9月6日-上午8时3 0分美国东部时间）
本回答由提问者推荐
已赞过
已踩过<
评论
收起
你对这个回答的评价是？
推荐律师服务：
若未解决您的问题，请您详细描述您的问题，通过百度律临进行免费专业咨询
